Executive Summary

- **Enormous Unmet Need for At-Home**, **Non-Invasive Tests** with **Instantaneous Results** for **Front Line Testing** to meet the demand of the more than **200 Million tests needed** with **only 25 Million tests available monthly**[2]

- **Smell Loss** is an **Early Indicator of COVID-19 Infection** and may **Occur in up to ~98%**[1] **of Patients**

- **Founded on 20 Years of Research in Olfactory Diagnostics,** the **COVID Smell Test** provides **Quantitative, Objective Smell Testing** and could **Identify Many Asymptomatic Carriers** with **Instantaneous Return of Results**

- **Aromha Smell Test** demonstrated **100% Sensitivity** and **67% Specificity** in **detecting smell loss related to COVID-19**

- **Aromha Smell Test** represents a **Safe Disposable At-Home Test** used with an **App** for **Cost-Effective Detection of Smell Loss due to COVID-19 in the $2 - $4 Billion Testing Market**

- As the **Population Ages**, increasing **Need for At-Home Monitoring of Brain Health** and **Neurodegenerative Disorders**

- **Early detection of Alzheimer's Disease** can help **Identify Appropriate Patients for Clinical Trials, Start Therapeutics Earlier** in the disease process, and provide **Cost-Effective Assessments of Cognitive Function in the $10.6 Billion Market**

1. Mullol, et al, The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries, *Curr Allergy Asthma Rep*.2020; 20(10): 61, August 3, 2020
2. S. Schachter and M. Kingsley, NIH RADx Tech Overview and Market Analysis Webinar October 13, 2020